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Abstract
Background: Human induced pluripotent stem (iPS) cells are currently used as powerful resources in regenerative medicine.
During very early developmental stages, DNA methylation decreases to an overall low level at the blastocyst stage, from
which embryonic stem cells are derived.Therefore, pluripotent stem cells, such as ES and iPS cells, are considered to have
hypo-methylated status compared to differentiated cells. However, epigenetic mechanisms of ‘‘stemness’’ remain unknown
in iPS cells derived from extra-embryonic and embryonic cells.
Methodology/Principal Findings: We examined genome-wide DNA methylation (24,949 CpG sites covering 1,3862 genes,
mostly selected from promoter regions) with six human iPS cell lines derived from human amniotic cells and fetal lung
fibroblasts as well as two human ES cell lines, and eight human differentiated cell lines using Illumina’s Infinium
HumanMethylation27. A considerable fraction (807 sites) exhibited a distinct difference in the methylation level between
the iPS/ES cells and differentiated cells, with 87.6% hyper-methylation seen in iPS/ES cells. However, a limited fraction of
CpG sites with hypo-methylation was found in promoters of genes encoding transcription factors. Thus, a group of genes
becomes active through a decrease of methylation in their promoters. Twenty-three genes including SOX15, SALL4, TDGF1,
PPP1R16B and SOX10 as well as POU5F1 were defined as genes with hypo-methylated SS-DMR (Stem cell-Specific
Differentially Methylated Region) and highly expression in iPS/ES cells.
Conclusions/Significance: We show that DNA methylation profile of human amniotic iPS cells as well as fibroblast iPS cells,
and defined the SS-DMRs. Knowledge of epigenetic information across iPS cells derived from different cell types can be
used as a signature for ‘‘stemness’’ and may allow us to screen for optimum iPS/ES cells and to validate and monitor iPS/ES
cell derivatives for human therapeutic applications.
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Introduction
Human embryonic stem (ES) cells [1] and induced pluripotent
stem (iPS) cells [2,3,4,5] are currently used as powerful resources
in regenerative medicine. However, epigenetic mechanisms of
‘‘stemness’’ remain unknown. DNA methylation is known to be a
key component in normal differentiation and development [6,7].
Tissue-specific genes, such as OCT-4/3 [8], Sry (sex determining
region on Y chromosome) [9] and MyoD [10], show tissue-specific
demethylation corresponding to their expression during develop-
ment. Furthermore, DNA methylation in cells specifically varies
depending on cell lineage and tissue types [7]. Transformation to
iPS cells from differentiated cells requires a process of epigenetic
reprogramming [11]. Understanding the epigenetic regulation in
human pluripotent stem cells, therefore, enable us to elucidate
‘‘stemness’’ and to screen for optimum iPS/ES cells for human
therapeutic applications. Human extra-embryonic amnion cells
are a useful cell source for generation of iPS cells, because they can
be collected without invasion and are conventionally freeze-
storable. Recently, we generated iPS cells from human amnion
cells as well as human fetal lung fibroblast cells [12,13]. Here, we
show DNA methylation profiles of human pluripotent stem cells
including iPS cells, which were derived from extra-embryonic
amnion cells and fetal lung fibroblast cells, and human ES cells.
We also defined another subset that may play a key practical role
in maintaining the state of ‘‘stemness’’.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13017Results
Analysis of genome-wide DNA methylation
Human iPS cell lines (MRC-iPS [13] and AM-iPS cell lines
[12]) independently established in our laboratory by retroviral
infection of 4 genes (OCT-3/4, SOX2, c-MYC, and KLF4), based on
the Yamanaka’s pioneer protocols [2] from 2 fully differentiated
cells (MRC-5, fetal lung fibroblast cells, and AM936EP, amnion
cells), were used as a primary source for experimentation (Table 1).
These cells clearly showed human iPS characters [12,13].
To examine DNA methylation status in six iPS, two ES [14],
and eight differentiated cell lines (Table 1), we therefore examined
genome-wide DNA methylation using Illumina’s Infinium Hu-
manMethylation27 BeadChip, on which oligonucleotides for
27,578 CpG sites covering more than 14,000 genes are mounted,
mostly selected from promoter regions. This assay system provides
advantageous quantitative measurement. DNA methylation levels
were recorded using a scoring system ranging from ‘‘0’’
(completely unmethylated) to ‘‘1’’ (fully-methylated). Using
multiple repetitions, we analyzed 24,949 out of 27,578 CpG sites
with 16 samples (see Materials and Methods), categorizing them
into three groups; Low (score#0.3), Middle (0.3,score#0.7), or
High (0.7,score) methylation. Overall, methylation levels in
pluripotent stem cells and differentiated cells are shown in Fig. 1A,
with the levels in each cell line presented in Table S1. While the
percentage of the High class in differentiated cells was 16.3% on
average, the percentage in iPS/ES cells was 25.3% (Fig. 1A). The
number of CpG sites categorized in the High class is significantly
greater in pluripotent stem cells compared with differentiated cells.
Hierarchical clustering analysis clearly discriminates iPS/ES cells
from the differentiated cells (Fig. 1B). Hyper-methylated sites
(shown in red) are widespread in the heat map in iPS/ES cells,
compared with the differentiated cells (Fig. 1B), suggesting that
gene promoters in iPS/ES cells are hyper-methylated, compared
with those in differentiated cells.
About two-thirds of the CpG sites were at a Low methylated
level in both iPS/ES cell and differentiated cell groups (Fig. 1A
and B). Another computation found 13,971 CpG sites to
consistently show a score of lower than 0.3. This suggests that a
significant fraction of the CpG sites examined may have less
involvement in methylation, although some might become
methylated under different conditions. As most CpG sites on the
chip were chosen simply based on the location in promoters, it is
possible that some CpG sites may be positioned at a distance from
the target site, even in a promoter controlled by DNA methylation.
Analysis of our and all published data indicated that a group of
CpG sites more suitable to methylation analyses could be
identified, allowing us to focus attention on specific changes in
methylation levels seen between iPS/ES and differentiated cells.
Differentially methylated site (DMS) in the promoters.
Firstly, we defined the ‘‘differentially methylated site’’ (DMS),
representing a CpG site whose score differed 0.3 points and more
between the two cell groups. The DMSs between MRC-iPS and
AM-iPS cells, and also between iPS and ES cells, were only 1.0%
and 2.8% of all the CpG sites, respectively (Fig. 1C), suggesting
that iPS and ES cells have similar methylation status. In contrast,
the DMSs between AM936EP and AM-iPS cells, and between
MRC-5 and MRC-iPS cells, were 11.3% and 10.6%, respectively,
suggesting that iPS cells and their parental cells have differentially
methylated status (Fig. 1C and D). It should be noted that
approximately 80% of the DMSs between the iPS cells and their
parental cells changed to a ‘‘hyper-methylated’’ state from a
‘‘hypo-methylated’’ state in iPS cells (Fig. 1C). Comparison of
DMSs between AM- and MRC-iPS cells, and between iPS and ES
cells show slight but significant difference (Fig. 1C). In 261 DMSs
between MRC- and AM-iPS cells (MA-DMSs), 203 sites in AM-
iPS cells and 165 in MRC-iPS cells showed no difference from
their parental cells, suggesting that these sites in iPS cells are
inherited from their tissue origin (Fig. 1E). In addition, 414 out of
694 DMSs between MRC-iPS and ES cells (ME-DMSs) and 581
out of 990 DMSs between AM-iPS and ES cells (AE-DMSs) are
inherited DMSs (Fig. 1E). Interestingly, approximately 40% of
DMSs between iPS and ES cells are iPS-specific DMSs, meaning
that these sites are aberrant methylated in iPS cells (Fig. 1E). In
Table 1. A list of human cells analyzed for a methylation state in this study.
Cell ID Description ability of differentiation
MRC5 Fetal lung fibroblast cells None
MRC-iPS-11 MRC5-derived iPS cells (P4) Pluripotent
MRC-iPS-19 MRC5-derived iPS cells (P4) Pluripotent
MRC-iPS-75 MRC5-derived iPS cells (P4) Pluripotent
AM936EP Amnion-derived cells (P6) None
AM-iPS-3 AM936EP -derived iPS cells (P4) Pluripotent
AM-iPS-6 AM936EP -derived iPS cells (P4) Pluripotent
AM-iPS-8 AM936EP -derived iPS cells (P4) Pluripotent
UtE1104 Endometrium-derived cells (P7) None
H4-1 Bone marrow stroma-derived cells (P26) None
Mim1508E Auricular cartilage-derived cells (P1) Cartilage
Yub636BM Extra finger bone marrow-derived cells (P3) Bone
PAE551 Placental artery endothelial cells (P13) None
Edom22 Menstrual blood-derived cells (P1) Myoblast
HUES3 Embryonic stem cells (P29) Pluripotent
HUES8 Embryonic stem cells (P24) Pluripotent
Numbers in parenthesis with P indicate passage in culture on the cells used in the methylation analysis.
doi:10.1371/journal.pone.0013017.t001
DNA Methylation in Human iPS
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e13017Figure 1. The ratio of hyper-methylated sites in iPS/ES cells was significantly larger than that of the differentiated cells. (A) Ratio of
Low (methylation score#0.3), Middle (0.3,score#0.7), and High (0.7,score) methylated states in 24,949 CpG sites. (B) Clustering analysis. Heat map
showing hyper-methylation in human iPS/ES cells compared with differentiated cells. The Heat map in hierarchical clustering analysis represented
DNA methylation levels from completely methylated (red) to unmethylated (green). Epigenetic distances (Euclidean Distance) were calculated by NIA
Array. (C) Comparisons of CpG sites between two groups show high similarities between AM-iPS and MRC-iPS cells or between human ES cells
(HUESCs) and iPS cells (iPSCs). In contrast, 11.3% and 10.6% of CpG sites are differentially methylated in AM-iPS and MRC-iPS cells, respectively,
compared to their parental cells (AM936EP and MRC5). It should be noted that 74.0% and 85.1% of the differentially methylated sites (DMSs) are
hyper-methylated in AM-iPS and MRC-iPS cells, respectively, compared to their parental cells. (D) Comparison of the 24,949 CpG sites between iPS
cells and their parental cells. (E) DMSs among human ES cells, AM- and MRC-iPS cells. The relative amount of inherited/aberrant DMSs is indicated in
the pie chart. (F) Overlapped aberrant DMSs between MRC- and AM-iPS cells.
doi:10.1371/journal.pone.0013017.g001
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PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e13017Figure 2. Pluripotent stem cells are significantly more hyper-methylated than differentiated cells. (A) Principal component analysis
(PCA) for DNA methylation states of 24,949 CpG sites with 16 human cell lines. The PC1 axis clearly distinguish iPS/ES cell group from differentiated
cells, while human iPS cells are very close to human ES cells. (B) Stem cell-specific differently methylated regions (SS-DMRs) were defined by PC1. In
the pluripotent stem cells, 60.5% of the SS-DMRs are located outside of CpG islands and 87.6% of the SS-DMRs are hyper-methylated. (C) DNA
methylation levels at promoter regions in 12 representative genes determined by Illumina Infinium HumanMethylation27 assay and Bio-COBRA.
DNA Methylation in Human iPS
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cells (Fig. 1F and data set S1, S2, S3). Overlapping aberrant DMSs
are located at promoters in genes such as gene for FZD10, MMP9
and three zinc finger proteins (ZNF551, ZNF513 and ZNF540).
These genes are hyper-methylated in iPS cells than parental cells
and ES cells. Approximately 80% of aberrant DMSs are hyper-
methylated, compared with parent cells and ES cells.
Defining stem cell specific differentially methylated
regions (SS-DMRs). Principal component analysis (PCA)
shows high similarity among human iPS and ES cells and
clearly separates the iPS/ES cells from the differentiated cells,
which is supported by hierarchical clustering analysis (Fig. 1B and
Fig. 2A). Based on principal component 1 (PC1), 807 (3.2%) out of
24,949 sites were deduced to change their methylation state along
with ‘‘stemness’’ (Fig. 2B). We designated a region represented by
such CpG sites as ‘‘stem cell specific differentially methylated
regions’’ (SS-DMRs). Of the 807 SS-DMRs, 39.5% (319 sites) are
localized on CpG islands, whereas 60.5% (488 sites) are not
(Fig. 2B), although 72.5% CpG sites on the bead-chips occur on
CpG islands. Thus, promoter regions on non-CpG islands were
more affected during reprogramming towards pluripotent stem
cells. 707 sites (87.6%) of the SS-DMRs were significantly
increased in the methylation levels in iPS/ES cells, compared
with those in the differentiated cells, and we designated these sites
as ‘‘stem cell specific hyper-differentially methylated regions (SS-
hyper-DMRs) ’’ (Fig. 2B and data set S4). In contrast, 100 sites
(12.4%) were decreased and designated as ‘‘stem cell specific hypo-
differentially methylated regions (SS-hypo-DMRs) ’’ (Fig. 2B and
data set S5). We also confirmed the methylation state in the
promoter regions for some of the detected genes by another
means, i.e. quantitative combined bisulfite restriction analysis
(COBRA) [15] (Fig. 2C). In addition, results of bisulfite sequencing
of the region surrounding the SS-DMRs corresponded to results of
Infinium assay and COBRA (Fig. 2D).
Gene ontology analysis with the SS-DMRs. We searched
gene ontology databases for details of the SS-DMRs. Interestingly,
SS-hypo-DMRs are abundant in genes related to nucleic acid
binding and transcription factors, which may function in iPS cells.
On the other hands, SS-hyper-DMRs are abundant in genes
related to differentiation (Table 2). We also subjected the SS-
DMRs to KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathway. Cytokine receptor interaction cascade, MAPK signaling,
and Neuroactive ligand-receptor interaction are all major
keywords for SS-hyper-DMRs (Table S2).
Expression of genes with SS-DMRs in human iPS/ES
cells. To address whether changes in DNA methylation state
are associated with expression levels, we surveyed genes showing
more than 5-fold change of expression in human iPS/ES cells,
compared with those in differentiated cells, using the GEO
database [16,17]. Twenty-three genes represented by SS-hypo-
DMRs were found in ‘‘genes significantly expressed in iPS/ES
cells’’ (Table 3 and Table S3A). Representative genes, including
SOX15, SALL4, TDGF1, PPP1R16B and SOX10, are expressed
with hypo-methylation states in iPS/ES cells (Fig. 3A). On the
other hand, forty-three genes represented by SS-hyper-DMRs
were found in ‘‘genes significantly suppressed in iPS/ES cells’’
(Table S3B and S4). Representative genes, SP100 and GBP3, are
suppressed by hyper-methylation in iPS/ES cells (Fig. 3A). Among
DNA methyltransferases, DNMT3B was reported to be highly
expressed in human ES cells [18]. DNMT3A, DNMT3B and
DNMT3L were indeed expressed in iPS/ES cells (Fig. 3A). The
DNMT3A promoter in iPS/ES cells became demethylated, while
DNMT3B and DNMT3L promoters remained low methylated
during reprogramming (Fig. 3A and Table S5A), leading us to
analyze chromatin in iPS/ES cells in addition to DNA
methylation.
Histone H3K4 and H3K27 modification of genes with the
SS-DMRs. Histone modification is another important
mechanism in epigenetics. Methylation of lysine 4 (K4) and 27
(K27) on histone H3 is associated with active and silent gene
expression, respectively [19], while bivalent trimethylation (me3)
of H3K4 and K27 represses their gene expression in ES cells
[20,21]. Based on the database of the UCSC Genome
Bioinformatics, the promoter of DNMT3B in human ES cells is
highly modified by 3K4me3, compared with that in human lung
fibroblasts (Table S5B). No differences in histone modification of
H3K4me3 or H3K27me3 between ES and lung fibroblasts at
promoter of DNMT3L were detected (Table S5B). We also
compared DNA methylation of the SS-DMRs with reported data
for whole-genome mapping of H3K4me3 and H3K27me3 in the
promoter regions of human ES cells [22]. In SS-hyper-DMRs,
68.8% do not have trimethylation of H3K4 and K27 (Fig. 3B). On
the other hand, 42.3%, 1.3%, and 30.8% of SS-hypo-DMRs are
marked with H3K4me3, H3K27me3, and bivalent H3K4me3 and
K27me3, respectively (Fig. 3B). Thirteen out of the 23 genes in
Table 2. A list of top 7 categories of GO Term in ‘‘SS-DMRs’’.
Molecular Function
PantherID: GO Term Count. Genes %
SS-hypo-DMRs
MF00042:Nucleic acid binding 30 41.10%
MF00036:Transcription factor 15 20.55%
MF00099:Small GTPase 11 15.07%
MF00137:Glycosyltransferase 8 10.96%
MF00082:Transporter 6 8.22%
MF00154:Metalloprotease 6 8.22%
MF00098:Large G-protein 6 8.22%
SS-hyper-DMRs
MF00213:Non-receptor serine/threonine
protein kinase
124 20.98%
MF00262:Non-motor actin binding protein 119 20.14%
MF00001:Receptor 80 13.54%
MF00131:Transferase 76 12.86%
MF00099:Small GTPase 66 11.17%
MF00242:RNA helicase 57 9.64%
MF00261:Actin binding cytoskeletal protein 53 8.97%
doi:10.1371/journal.pone.0013017.t002
Details of these genes are described in Table S6B. The promoter regions of these genes were defined as the SS-DMRs. The relative amount of
methylated DNA ratio is indicated as the black area in the pie chart. The same methylation patterns in 12 regions were detected both by Infinium
assay and COBRA. (D) Bisulfite sequencing analysis of the same regions that were analyzed by Infinium assay and COBRA assay in SOX15, SALL4, SP100
and GBP3. (Top) Schematic diagram of the genes. Arrows, open boxes and open circles represent transcription start site, first exon and position of
CpG sites, respectively. (Bottom) Open and closed circles indicate unmethylated and methylated states, respectively. Red and blue arrowheads
represent the position of CpG sites in Infinium assay and COBRA, respectively.
doi:10.1371/journal.pone.0013017.g002
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no histone trimethylation on K4 and K27 and the rest have
bivalent K4/K27 trimethylation (Fig. 3C).
Discussion
Our genome-wide DNA methylation analysis shows that iPS
and ES cells have similar methylation status although DNA
methylation status of AM-iPS cells was closer to that of MRC-iPS
cells than to that of ES cells in a small fraction. Doi et al. reported
71 differential methylated regions covering 64 genes between
human iPS cells and ES cells [23]. Comparison of 535 aberrant
DMSs (overlapping, 155; MRC-iPS specific, 125; AM-iPS specific,
255) with Doi’s data, six genes that are HOXA9, A2BP1, FZD10,
SOX2, PTPRT and HYPK overlapped. The inconsistency of most
DMSs may be due to the stochastic nature of aberrant methylation
through the genome. Human iPS and ES cells have general hyper-
methylated status compared with differentiated cells. Our present
genome-wide study indicates that pluripotent stem cells are
generally hyper-methylated at promoter regions in comparison
with differentiated cells. In the SS-DMRs, the number of CpG
sites on non-CpG islands is grater than those on CpG islands,
suggesting that promoter regions on non-CpG islands were more
affected during reprogramming towards pluripotent stem cells.
This result is consistent with the suggestion by Fouse et al. (2008)
[24] that DNA methylation in mouse ES cells primarily occurred
on non-CpG island regions of promoters.
Gene ontology analysis shows that signal transduction and
transmembrane are major keywords for SS-hyper-DMRs. Most
genes with SS-hyper-DMRs relate to differentiation. Recent
studies demonstrate that blocking the p53 and TGFß pathways
improves efficiency of generation of iPS cells [25,26,27,28,29,30].
Some genes related to these pathways are included in SS-hyper-
DMR. Approximately 70% of SS-hyper-DMR have no modifica-
tion of H3K4 and H3K27, suggesting that most genes with SS-
hyper-DMRs are rigorously turned off by DNA methylation. By
combining these findings with the result of DNMT3A, DNMT3B
and DNMT3L induction in iPS/ES cells, we suggest that SS-hyper-
DMRs apparently include genes that play a role in differentiated
cells. Moreover, they must be silenced by DNMTs to establish
pluripotency. We then identified 43 genes with SS-hyper-DMRs
from ‘‘genes significantly suppressed in iPS/ES cells’’ (Table S3B
and S4). In particular, GBP3 and SP100 could be used as
epigenetic markers for pluripotency.
In addition, we successfully determined 23 genes with SS-hypo-
DMRs from ‘‘genes significantly expressed in iPS/ES cells’’
(Table 3 and Table S3A). Those genes may start to be induced by
demethylation and a significant subset of genes that act for de-
Table 3. A list of 23 genes with SS-hypo-DMRs exhibiting ‘high’ expression in human iPS/ES cells.
TargetID Gene name
Fold change of
expression
DNA methylation
level in iPS/ES cells
DNA methylation
level in Diff. cells
cg07337598 ANXA9, annexin A9 5.53 0.29460.023 0.71260.014
cg24183173 BCOR, BCL-6 interacting corepressor 5.06 0.01460.005 0.78460.051
cg21207436 C14orf115, hypothetical protein LOC55237 63.49 0.05260.005 0.44260.036
cg22892904 CBX2, chromobox homolog 2 11.48 0.06860.006 0.60760.051
cg24754277 DAPK1, death-associated protein kinase 1 28.34 0.11560.005 0.70860.049
cg21629895 DNMT3A, DNA cytosine methyltransferase 3 alpha 12.88 0.45260.011 0.76960.039
cg02932167 ECEL1, endothelin converting enzyme-like 1 17.57 0.11560.007 0.67260.059
cg25431974 ECEL1, endothelin converting enzyme-like 1 17.57 0.12560.013 0.67460.093
cg04515567 FOXH1, forkhead box H1 55.88 0.60260.014 0.85560.006
cg04464446 GAL, galanin preproprotein 194.63 0.24160.022 0.73560.056
cg00943909 GNAS, guanine nucleotide binding protein 47.33 0.07660.016 0.52860.081
cg27661264 GNAS, guanine nucleotide binding protein 47.33 0.03760.005 0.35560.054
cg18741908 GPR160, G protein-coupled receptor 160 60.48 0.06860.006 0.46660.038
cg20674521 KCNJ4, potassium inwardly-rectifying channel J4 6.11 0.30660.024 0.77260.043
cg21129531 LRRC4, netrin-G1 ligand 7.04 0.02760.004 0.78860.058
cg06144905 PIPOX, L-pipecolic acid oxidase 42.97 0.10060.015 0.55860.080
cg13083810 POU5F1, POU domain; class 5; 559.14 0.56360.025 0.91960.009
cg27377213 PPP1R16B, protein phosphatase 1 regulatory
inhibitor subunit 16B
65.86 0.09760.009 0.79660.102
cg19580810 RAB25, member RAS oncogene family 6.16 0.06260.010 0.70360.030
cg09243900 RAB25, member RAS oncogene family 6.16 0.10560.013 0.59560.031
cg06303238 SALL4, sal-like 4 227.35 0.01360.005 0.73660.075
cg06614002 SOX10, SRY-box 10 5.23 0.02860.005 0.82960.046
cg01029592 SOX15, SRY-box 15 10.19 0.17460.011 0.69260.032
cg10242476 TDGF1, teratocarcinoma-derived growth factor 1 2472.59 0.14660.013 0.38760.052
cg20277416 TM7SF2, transmembrane 7 superfamily member 2 5.23 0.38060.017 0.83360.027
cg05656364 VAMP8, vesicle-associated membrane protein 8 9.69 0.07060.010 0.69860.081
Fold change of expression: Fold change of expression of the listed gene in human iPS/ES cells against the expression level in differentiated cells.
doi:10.1371/journal.pone.0013017.t003
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global reprogramming. Promoters of most marker genes expressed
in human iPS/ES cells were low methylated in all cells examined
(Table S5C). Analysis of histone modification of H3K4me3 and
K27me3 from the database suggested that expression of DNMT3B
might be regulated by methylation of H3K4 but expression of
DNMT3L might not be under control of histone modification of
H3K4me3 and K27me3. Most genes with SS-hypo-DMRs
without expression in human iPS/ES cells have modification of
H3K4me, bivalent H3K4me/K27me, or none, but do not have
H3K27me3 modification. These genes may therefore be ready to
be activated upon differentiation.
These findings are in generally consistent with the previous
reports that have compared methylation profiles in somatic cells,
iPS cells, and ES cells [23,31,32]. However, their analyses were
limited only to human fibroblasts as a source for generation of iPS
cells. In this study, we analyzed human extra-embryonic amnion
cells and iPS cells. The DNA methylation profile at promoter sites
clearly distinguished human pluripotent stem cells from differen-
tiated cells. The SS-DMRs defined in this experiment can be used
as a signature for ‘‘stemness’’. In addition, knowledge of the DNA
methylation profile in human ES and iPS cells derived from
different cell types is absolutely imperative and may allow us to
screen for optimum iPS/ES cells and to validate and monitor iPS/
ES cell derivatives for human therapeutic applications.
Materials and Methods
Human Cells
Human endometrium, bone marrow stroma, auricular carti-
lage, extra finger bone marrow, amnion, placental artery
endothelium and menstrual blood cells were collected by scraping
tissues from surgical specimens as a therapy, under signed
informed consent, with ethical approval of the Institutional
Review Board of the National Institute for Child Health and
Development, Japan. Signed informed consent was obtained from
Figure 3. Expression and histone modification of the SS-DMRs related genes. (A) Expression patterns of representative genes. RT-PCR
analysis of 7 representative genes and methyltransferase genes. Methylation levels (Me) of each promoter are shown under each panel. H=High
methylation (0.7,score); M=Middle methylation (0.3,score#0.7); L=Low methylation (score#0.3). (B) Comparable distribution of the SS-DMR and
histone trimethylation (me3) of H3K4 and H3K27. Percentage of H3K4me3, H3K27me3, bivalent H3K4me3/K27me3 or non-modification on genes in
SS-hyper-DMRs and in SS-hypo-DMRs. (C) Histone modification of 23 genes in Table 3.
doi:10.1371/journal.pone.0013017.g003
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All experiments handling human cells and tissues were performed
in line with Tenets of the Declaration of Helsinki. Endometrium
(UtE1104), bone marrow stroma (H4-1) [33], auricular cartilage
(Mim1508E), extra finger bone marrow (Yub636BM), amnion
(AM936EP), placental artery endothelium (PAE551) and men-
strual blood cell (Edom22) [34] cell lines were independently
established in our laboratory. H4-1, Mim1508E, Yub636BM,
AM936EP, Edom22, and MRC-5 [35] cells were maintained in
the POWEREDBY10 medium (MED SHIROTORI CO., Ltd,
Tokyo, Japan). PAE551 were cultured in EGM-2MV BulletKit
(Lonza, Walkersville, MD, USA) containing 5% FBS. Human
induced pluripotent stem (iPS) cells were generated, via procedures
described by Yamanaka and colleagues [2] with slight modifica-
tion. Human iPS cell lines derived from MRC-5 were designated
as MRC-iPS cells [13], also iPS cell lines from AM936EP were
named as AM-iPS cells [12]. Human iPS cells were maintained in
iPSellon medium (Cardio Incorporated, Osaka, Japan) supple-
mented with 10 ng/ml recombinant human basic fibroblast
growth factor (bFGF, Wako Pure Chemical Industries, Ltd.,
Osaka, Japan). Frozen pellets of human ES cell (HUESCs) were
kindly gifted from Drs. C. Cowan and T. Tenzan (Harvard Stem
Cell Institute, Harvard University, Cambridge, MA).
Illumina Infinium HumanMethylation27 BeadChip assay
Genomic DNA was extracted from cells using the QIAamp
DNA Mini Kit (Qiagen). One microgram of genomic DNA from
each sample was bisulfite-converted using EZ DNA Methylation-
Gold kit (Zymo Research), according to the manufacturer’s
recommendations. Bisulfite-converted DNA was hybridized to
the HumanMethylation27 BeadChip (Illumina inc.). Methyla-
tion levels of each CpG site were determined with fluorescent
signals for methylated and unmethylated alleles. Methylated and
unmethylated signals were used to compute a Beta value, which
was a quantitative score of DNA methylation levels ranging from
‘‘0’’, for completely unmethylated, to ‘‘1’’, for completely
methylated. On the HumanMethylation27 BeadChip, oligonu-
cleotides for 27,578 CpG sites covering more than 14,000 genes
are mounted, mostly selected from promoter regions. 26,956
(97.7%) out of the 27,578 CpG sites are set at promoters and
20,006 (72.5%) sites are set on CpG islands. CpG sites with
$0.05 ‘‘Detection p value’’ (computed from the background
based on negative controls) were eliminated from the data for
further analysis, leaving 24,949 valid for use with the 16 samples
tested.
Analysis of DNA methylation data
To analyze DNA methylation data, we used the following web
tools: TIGR MeV [36] (http://www.tm4.org/mev.html) for
hierarchical clustering heat map, NIA Array [37] (http://lgsun.
grc.nia.nih.gov/ANOVA/) for hierarchical clustering that classify
DNA methylation data by similarity and for principal component
analysis (PCA) that finds major component in data variability,
DAVID Bioinformatics Resources [38] (http://david.abcc.ncifcrf.
gov/home.jsp), PANTHER Classification System [39] (http://
www.pantherdb.org/), WebGestalt [40] (WEB-based GEne SeT
AnaLysis Toolkit) (http://bioinfo.vanderbilt.edu/webgestalt/)
based on based on KEGG (Kyoto Encyclopedia of Genes and
Genomes) database [41] (http://www.genome.jp/kegg/) for gene
ontology analysis, the GEO database (http://www.ncbi.nlm.nih.
gov/geo/) for surveying gene expression in human iPS/ES cells
(accession no. GSE9832 [16] and GSE12583 [17]), and the
UCSC Genome Browser website [42] (http://genome.ucsc.edu/).
RT-PCR
RNA was extracted from cells using the RNeasy Plus Mini kit
(Qiagen). An aliquot of total RNA was reverse transcribed using
random hexamer primers. The cDNA template was amplified
using specific primers for SOX10, SOX15, PPP1R16B, SALL4,
TDGF1, Sp100 and GBP3. Expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a positive
control. Primers used in this study are summarized in Table S6A.
Quantitative combined bisulfite restriction analysis
(COBRA) and bisulfite sequencing
To confirm DNA methylation state, bisulfite PCR-mediated
restriction mapping (known as the COBRA method) was
performed. Sodium bisulfite treatment of genomic DNA was
carried out as described above. PCR amplification was performed
using IMMOLASE
TM DNA polymerase (Bioline Ltd; London,
UK) and specific primers (Table S6B). After digestion with
restriction enzymes, HpyCH4IV or Taq I, quantitative-COBRA
coupled with the Shimadzu MCEH-202 MultiNA platform
(Shimadzu, Japan) known as the Bio-COBRA method was carried
out for quantitative DNA methylation level. Information of
primers and restriction enzyme is summarized in Table S6B. To
determine the methylation status of individual CpG in SOX15,
SALL4, Sp100 and GBP3, the PCR product was gel extracted and
subcloned into pGEM T Easy vector (Promega, Madison, WI),
and then sequenced. Methylation sites were visualized and quality
control was carried out by the web-based tool, ‘‘QUMA’’ (http://
quma.cdb.riken.jp/) [43].
Supporting Information
Table S1 Frequency of methylation states in each cell line.
Found at: doi:10.1371/journal.pone.0013017.s001 (0.04 MB
PDF)
Table S2 A list of genes with SS-hyper-DMRs and SS-hypo-
DMRs on KEGG Pathway.
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in Table 3, (B) DNA methylation states of 43 genes (50 CpG sites)
in Table S4.
Found at: doi:10.1371/journal.pone.0013017.s003 (1.61 MB
PDF)
Table S4 A list of 43 genes with SS-hyper-DMRs exhibiting
‘low’ expression in human iPS/ES cells.
Found at: doi:10.1371/journal.pone.0013017.s004 (0.07 MB
PDF)
Table S5 (A) DNA methylation states of DNA methyltransfer-
ases, (B) Histone methylation states of DNA methyltransferases,
(C) DNA methylation states of marker genes in human iPS/ES
cells.
Found at: doi:10.1371/journal.pone.0013017.s005 (0.57 MB
PDF)
Table S6 (A) primers used for RT-PCR, and (B) primers used
for COBRA.
Found at: doi:10.1371/journal.pone.0013017.s006 (0.52 MB
PDF)
Data set S1 A list of overlapped aberrant DMSs.
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XLS)
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